Loading
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Previous close
$2.20
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Day range
Current $2.20
52-week range
Current $2.20
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
56
Mixed
Risk
46
Elevated Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Day range
Current $2.20
52-week range
Current $2.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 4.01M USD | 18.39M USD |
| Cost of goods sold | 1.69M USD | — | — | 651K USD | 5.82M USD |
| Gross profit | −1.69M USD | — | — | 3.36M USD | 12.57M USD |
| Research and development | 47.39M USD | 37.76M USD | 32.85M USD | 31.54M USD | 28.27M USD |
| Selling, general, and administrative | 8.3M USD | 4.71M USD | 4.66M USD | 6.31M USD | 9.39M USD |
| Operating expenses | 54M USD | 42.47M USD | 37.51M USD | 37.85M USD | 37.66M USD |
| Interest income | 5.68M USD | 9.81M USD | 10.42M USD | 3.82M USD | 467K USD |
| Interest expense | 88K USD | 807K USD | — | — | — |
| Depreciation and amortization | 1.69M USD | 1.75M USD | 1.74M USD | 2.61M USD | 2.65M USD |
| Operating income | −55.69M USD | −42.47M USD | −37.51M USD | −34.49M USD | −25.08M USD |
| Net income | −45.54M USD | −38.53M USD | −24.56M USD | −32.9M USD | −17.41M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 15, 2021 | $2.50Special | Jul 16, 2021 | Jul 23, 2021 |
Ex-dividend Jul 15, 2021
$2.50
Special
Record Jul 16, 2021 · Payment Jul 23, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
EA Bridgeway Omni Small-Cap Value ETFBSVO
Avantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
